logo-loader
Humanigen Inc

Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal

The study involving lenzilumab showed a reduction in cytokine release syndrome and neuroinflammation as well as an enhancement in CAR-T cell function

Dr Cameron Durrant
Dr Cameron Durrant, CEO of Humanigen, says the study marks a ‘significant advance’

Humanigen Inc (OTCMKTS:HGEN) said  Friday that the editors of the medical journal blood featured on the cover of the current edition, a study of the use of the company's proprietary monoclonal antibody.

The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells. The study involving lenzilumab showed a reduction in cytokine release syndrome and neuroinflammation as well as an enhancement in CAR-T cell function, according to the Burlingame, California, company.

READ: Sonavex to begin commercial roll-out of its blood clot detection device Q1 2019

The study, conducted with lab mice, was designed to replicate the effects seen in CAR-T clinical trials. It used human acute lymphoblastic leukemia cells, human CD19 targeted CAR-T (CART19) cells and human peripheral blood mononuclear cells.

The use of lenzilumab with CART19 therapy resulted in significant improvement in leukemic disease control, sustained for at least 35 days after CART19 administration, compared with a control, according to Humanigen.  

“This work represents a significant advance in understanding how to improve efficacy and safety of CAR-T,” Dr Cameron Durrant, CEO of Humanigen, said in a statement.

Shares of the company rose 1.1% to $0.93 in Thursday’s OTC Markets trading.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Humanigen Inc

Price: $0.82

Market: OTCQB
Market Cap: $92.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen inks licensing agreement with the University of Zurich to...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers. Durrant says Humanigen has received an exclusive licensing...

on 07/22/2019

2 min read